Brief: Data Study Of Patients With High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance Of Decisiondx-SCC
19/05/2022 12:05
May 19 (Reuters) - Castle Biosciences Inc CSTL.O :
* DATA FROM SECOND INDEPENDENT MULTI-CENTER STUDY OF PATIENTS WITH HIGH-RISK
CUTANEOUS SQUAMOUS CELL CARCINOMA CONFIRMS INDEPENDENT RISK-STRATIFICATION
PERFORMANCE OF DECISIONDX®-SCC
Source text for Eikon: ID:nBw8GVHgxa
Further company coverage: CSTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Castle Biosciences
See all newsBrief: Castle Biosciences, - Opens New Laboratory And Office Facility In Scottsdale, Arizona
U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina
Castle Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Castle Biosciences beats Q2 revenue estimates, hikes forecast
Brief: Castle Biosciences Q2 Revenue USD 103.546 Million Vs. IBES Estimate USD 86.2 Million